"Terlipressin in the treatment of septic shock: the earlier the better?"

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 2, 2008, Pages 317-321

  Morelli, Andrea ^a   Ertmer, Christian ^b   Westphal, Martin ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

adverse effects; sepsis; septic shock; terlipressin; vasopressin

Indexed keywords

ARGIPRESSIN; CATECHOLAMINE; NORADRENALIN; TERLIPRESSIN; VASOPRESSIN;

ADJUVANT THERAPY; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EARLY INTERVENTION; FLUID RESUSCITATION; HEART MUSCLE INJURY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; LIVER INJURY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN NECROSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ANIMALS; HUMANS; LYSINE VASOPRESSIN; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 44949135012     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.02.006     Document Type: Review

References (14)

1. Westphal M., Stubbe H., Sielenkamper A.W., et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Medicine 29 (2003) 301-308
2. O'Brien A., Clapp L., and Singer M. Terlipressin for norepinephrine-resistant septic shock. The Lancet 359 (2002) 1209-1210
3. Morelli A., Rocco M., Conti G., et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Medicine 30 (2004) 597-604
4. Leone M., Albanese J., Delmas A., et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 22 (2004) 314-319
5. Albanese J., Leone M., Delmas A., and Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine 33 (2005) 1897-1902
6. Morelli A., Ertmer C., Lange M., and Westphal M. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?. Intensive Care Medicine 33 (2007) 1669-1670
7. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine 345 (2001) 1368-1377
8. Rivers E.P., Kruse J.A., Jacobsen G., et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Critical Care Medicine 35 (2007) 2016-2024
9. Russell J.A., Walley K.R., Singer J., et al., the VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Eng J Med 358 (2008) 877-887
10. Vincent J.L. The International Sepsis Forum's frontiers in sepsis: high cardiac output should be maintained in severe sepsis. Critical Care 7 (2003) 276-278
11. Sharma V.K., and Dellinger R.P. The International Sepsis Forum's frontiers in sepsis: high cardiac output should not be maintained in severe sepsis. Critical Care 7 (2003) 272-275
12. Lange M., Koehler G., Morelli A., et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28 (2007) 623-629
13. Jolley D.H., De Keulenaer B.L., Potter A., et al. Terlipressin infusion in catecholamine-resistant shock. Anaesthesia and Intensive Care 31 (2003) 560-564
14. Umgelter A., Reindl W., Schmid R.M., et al. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Medicine 34 (2008) 390-391